Literature DB >> 24319177

Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers.

Tait Shanafelt1.   

Abstract

Despite the advanced age at onset, chronic lymphocytic leukemia (CLL) shortens the life expectancy of the majority of newly diagnosed patients. The management of elderly patients with CLL is more complex than that of younger patients due to the greater frequency of comorbidities and functional impairment as well as reduced organ function. Many of the recent advances in the care of CLL patients (prognostication, more intense combination therapy regimens) are of unclear relevance for elderly patients. This review addresses 5 key questions in the management of elderly patients with CLL: (1) why is classifying the "fitness" of CLL patients necessary; (2) what criteria should be used to classify patient fitness; (3) when should elderly patients be treated; (4) how should therapy be selected for elderly patients; and (5) which therapy is best (for this patient)?

Entities:  

Mesh:

Year:  2013        PMID: 24319177     DOI: 10.1182/asheducation-2013.1.158

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  21 in total

Review 1.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Authors:  Philip A Thompson; William G Wierda
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

Review 2.  Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?

Authors:  Fabienne McClanahan; John Gribben
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-26       Impact factor: 3.722

3.  Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients.

Authors:  Gina Zini; Marie C Béné
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

4.  Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.

Authors:  C Owen; A S Gerrie; V Banerji; S Assouline; C Chen; K S Robinson; E Lye; G Fraser
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

Review 5.  Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future.

Authors:  Francesco Merli; Caterina Mammi; Fiorella Ilariucci
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

6.  Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

Authors:  Ronald de Vries; Johan W Smit; Peter Hellemans; James Jiao; Joseph Murphy; Donna Skee; Jan Snoeys; Juthamas Sukbuntherng; Maarten Vliegen; Loeckie de Zwart; Erik Mannaert; Jan de Jong
Journal:  Br J Clin Pharmacol       Date:  2016-01-15       Impact factor: 4.335

Review 7.  Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach.

Authors:  Paolo Strati; Alessandra Ferrajoli
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

8.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Authors:  Ian W Flinn; Peter Hillmen; Marco Montillo; Zsolt Nagy; Árpád Illés; Gabriel Etienne; Julio Delgado; Bryone J Kuss; Constantine S Tam; Zoltán Gasztonyi; Fritz Offner; Scott Lunin; Francesco Bosch; Matthew S Davids; Nicole Lamanna; Ulrich Jaeger; Paolo Ghia; Florence Cymbalista; Craig A Portell; Alan P Skarbnik; Amanda F Cashen; David T Weaver; Virginia M Kelly; Barry Turnbull; Stephan Stilgenbauer
Journal:  Blood       Date:  2018-10-04       Impact factor: 22.113

Review 9.  The cancer patient and cardiology.

Authors:  José Luis Zamorano; Christer Gottfridsson; Riccardo Asteggiano; Dan Atar; Lina Badimon; Jeroen J Bax; Daniela Cardinale; Antonella Cardone; Elizabeth A M Feijen; Péter Ferdinandy; Teresa López-Fernández; Chris P Gale; John H Maduro; Javid Moslehi; Torbjørn Omland; Juan Carlos Plana Gomez; Jessica Scott; Thomas M Suter; Giorgio Minotti
Journal:  Eur J Heart Fail       Date:  2020-10-02       Impact factor: 15.534

Review 10.  Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

Authors:  Sarah E M Herman; Adrian Wiestner
Journal:  Semin Oncol       Date:  2016-02-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.